Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9596 posts found.

ViiV Healthcares scores first twin-drug FDA approval for untreated HIV-1

April 9, 2019 Manufacturing and Production, Research and Development GSK, HIV, ViiV Healthcare, pharma

ViiV Healthcare, the pharmaceutical firm owned by Shionogi, Pfizer and predominantly GSK, has announced its two-drug HIV regimen Dovato (dolutegravir …
News
simon-sturge-kymab-tile

Kymab announces Merck exec Simon Sturge as new CEO

April 8, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, appointment, kymab, pharma

UK-based biotech Kymab has identified Merck KGaA executive Simon Sturge as its new Chief Executive Officer, taking over the reins …
Appointment
real_world

Protecting public health: Is real-world evidence the key?

April 8, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing feature, pharma, real world data, real world evidence, real-world data, real-world evidence

In often tough regulatory climates and with threats to public health are growing in sceptical corners of society, the need …
Feature

NICE turns down Astellas’ Xtandi in prostate cancer

April 8, 2019 Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer

Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for …
News
shutterstock_159488225

Alnylam and Sanofi close research phase of 2014’s $700m RNAi rare disease partnership

April 8, 2019 Research and Development, Sales and Marketing Alnylam, Genzyme, Sanofi, pharma, rare disease

Alnylam and Sanofi have announced their intention to bring to an end the research and option phase of a $700 …
News
x_ray_health_arm_doctors_medicine_bone_hospital_medical_insurance-480473

Osteoporisis risk in over half of European women over 70, three-quarters not treated, Amgen study finds

April 8, 2019 Research and Development, Sales and Marketing Amgen, Europe, UK, bones, osteoporosis, pharma, real world data, real-world data

A new study from Amgen analysing real-world data has revealed that more than half of European women over 70 years …
News
shutterstock_243110086

Merrimack shuts down development of investigational cancer drug, staff cuts to follow

April 8, 2019 Research and Development, Sales and Marketing cacner, merrimack, oncology, pharma

Merrimack Pharmaceuticals has taken the decision to terminate development of its antibody-directed nanotherapeutic cancer therapy MM-310 in the treatment of …
News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 5, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, Northern Ireland, Novartis, Placebo, UK, brexit, pharma

As Brexit looms, pharma trade lobby the ABPI called for a ban on exports of medicines in the case of …
News

Memorial Sloan Kettering Cancer Center officials violated conflict of interest policies

April 5, 2019 Medical Communications, Research and Development Cancer, Memorial Sloan Kettering Cancer Center, oncology, research

Top officials at the Memorial Sloan Kettering Cancer Center repeatedly violated policies on financial conflicts of interest, according to details …
News
theo_harold

Crescendo Biologics selects current CFO Theodora Harold as new CEO

April 4, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Cambridge, Crescendo Biologics, Dr Peter Pack, Theo Harold, cfo

Cambridge, UK-based Crescendo Biologics have said current Chief Financial Officer (CFO) Theodora Harold will take over from Dr Peter Pack …
Appointment
astrazeneca-sign

AstraZeneca’s early-stage Fasenra study smashes primary endpoint in hypereosinophilic syndrome

April 4, 2019 Research and Development AstraZeneca, Fasenra, hypereosinophilic syndrome, pharma

AstraZeneca has revealed new data for Fasenra (benralizumab), demonstrating that patients using the drug can “achieve near-complete depletion of eosinophils …
News
nhs_andrew_tatlow

NHS England threatened legal action against Oxford University hospitals trust

April 4, 2019 Medical Communications, Research and Development Hopsitals, NHS, NHS England, OUH, cancer screening, patients

NHS England threatened to sue Oxford University hospitals (OUH) NHS trust after they objected to the former’s controversial decision to …
News

HPV vaccine prevents 90% of cervical pre-cancer cases in Scotland, research shows

April 4, 2019 Research and Development HPV, Scotland, cervical cancer, immunity, vaccines, virus

Routine vaccination of girls in Scotland against HPV has led to a dramatic drop in cases of cervical cancer, according …
News

Sangamo and Pfizer’s gene therapy increases FVIII activity in severe haemophilia A in early study

April 3, 2019 Research and Development, Sales and Marketing Pfizer, Sangamo, haemophilia, pharma

Sangamo Therapeutics and Pfizer have unveiled new Phase 1/2 data for their jointly developed investigational gene therapy SB-525, demonstrating that …
News
psm_v46_d168_mesial_view_of_the_human_brain

Children born in poverty show major differences in brain function, study shows

April 3, 2019 Research and Development India, UEA, brain development, brain function, childhood, children

Children born into poverty show major differences in early brain function, according to research from the University of East Anglia. …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026